Trans-Nasal Delivery: A Review of Opportunities and Challenges to Cross the Blood Brain Barrier
Trans-nasal drug delivery offers great potential to treat an array of unmet medical needs in CNS (Central Nervous System) disorders that affect millions of people today. The ability of many drugs to cross the BBB (Blood Brain Barrier) is constrained by their physiochemical properties, leading to sub-therapeutic concentrations in the CNS as well as problematic side effects due to systemic drug exposure.
This review aims to inform the reader about both the opportunities and challenges associated with trans-nasal delivery of therapies across the BBB to treat CNS disorders. Areas covered will include physiochemical barriers, formulations, delivery devices, quantifying uptake and transition from current pre-clinical work to successful human clinical trials and the paper incorporates current literature on the subject.
Much of the underlying research and pre-clinical work has been successfully executed in trans-nasal drug delivery to target CNS diseases. The main challenge lies in the transition from animal to human clinical studies establishing robust regulatory dossiers that will satisfy the regulators that these therapies are both efficacious and safe to treat the target CNS diseases at a commercial scale.
Julie Suman1*, Gerallt Williams2
To read the full article Download Full Article | Visit Full Article
Menu